AR044697A1 - Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato - Google Patents
Formulaciones farmaceuticas que comprenden amoxicilina y clavulanatoInfo
- Publication number
- AR044697A1 AR044697A1 ARP040102062A ARP040102062A AR044697A1 AR 044697 A1 AR044697 A1 AR 044697A1 AR P040102062 A ARP040102062 A AR P040102062A AR P040102062 A ARP040102062 A AR P040102062A AR 044697 A1 AR044697 A1 AR 044697A1
- Authority
- AR
- Argentina
- Prior art keywords
- clavulanate
- amoxicillin
- amoxycline
- reconstitution
- formulation
- Prior art date
Links
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 title abstract 5
- 229940090805 clavulanate Drugs 0.000 title abstract 5
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 abstract 4
- 229960003022 amoxicillin Drugs 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 2
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulaciones que comprenden amoxicilina y clavulanato para reconstitución en una suspensión acuosa incorporan bajos niveles de carboximetilcelulosa de sodio para estabilizar el pH de las mismas. Reivindicación 1: Una formulación farmacéutica de amoxicilina y clavulanato proporcionada en forma de una composición en polvo seco adaptada para reconstitución con agua en una suspensión multidosis que comprende de aproximadamente 400 a aproximadamente 1250 mg de amoxicilina y de aproximadamente 40 a aproximadamente 90 mg de clavulanato por cantidad unitaria de formulación, de modo que la relación de amoxicilina a clavulanato es de al menos 10:1, y que comprende además un agente estabilizante del pH que es carboximetilcelulosa de sodio y excipientes farmacéuticamente aceptables. Reivindicación 18: Una formulación según una cualquiera de las reivindicaciones 1 a 15 para tratar infecciones bacterianas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47876903P | 2003-06-16 | 2003-06-16 | |
| GBGB0313913.6A GB0313913D0 (en) | 2003-06-16 | 2003-06-16 | New use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044697A1 true AR044697A1 (es) | 2005-09-21 |
Family
ID=27636629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102062A AR044697A1 (es) | 2003-06-16 | 2004-06-14 | Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050136117A1 (es) |
| CN (1) | CN1809348A (es) |
| AR (1) | AR044697A1 (es) |
| GB (1) | GB0313913D0 (es) |
| TW (1) | TW200509990A (es) |
| ZA (1) | ZA200510098B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007002924A1 (de) * | 2007-01-19 | 2008-07-24 | Bayer Healthcare Ag | ß-Lactam-haltige Formulierungen mit erhöhter Stabilität in wässriger Lösung |
| EP2802327A1 (en) | 2012-01-10 | 2014-11-19 | Michael Spector | Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and method for using same |
| CN102614174B (zh) * | 2012-02-24 | 2014-04-30 | 南京臣功制药股份有限公司 | 含有阿莫西林和克拉维酸钾的干混悬剂 |
| CN104345100A (zh) * | 2014-08-29 | 2015-02-11 | 四川制药制剂有限公司 | 同时测定阿莫西林克拉维酸钾血药浓度的方法 |
| CN114668724B (zh) * | 2020-12-24 | 2023-08-22 | 鲁南制药集团股份有限公司 | 一种阿莫西林克拉维酸钾干混悬剂及其制备方法 |
| WO2025038953A1 (en) * | 2023-08-17 | 2025-02-20 | Veterinary Pharmacy Corporation | Formulations of aminopenicillin and methods for solubilizing aminopenicillin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1078627B1 (en) * | 1999-08-20 | 2006-08-02 | Laboratoire GlaxoSmithKline S.A.S. | Pharmaceutical formulation comprising amoxycillin and clavulanate |
-
2003
- 2003-06-16 GB GBGB0313913.6A patent/GB0313913D0/en not_active Ceased
-
2004
- 2004-06-14 TW TW093117060A patent/TW200509990A/zh unknown
- 2004-06-14 AR ARP040102062A patent/AR044697A1/es not_active Application Discontinuation
- 2004-06-15 CN CNA2004800169527A patent/CN1809348A/zh active Pending
- 2004-06-15 US US10/868,104 patent/US20050136117A1/en not_active Abandoned
-
2005
- 2005-12-12 ZA ZA200510098A patent/ZA200510098B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1809348A (zh) | 2006-07-26 |
| ZA200510098B (en) | 2007-04-25 |
| GB0313913D0 (en) | 2003-07-23 |
| US20050136117A1 (en) | 2005-06-23 |
| TW200509990A (en) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5130023A1 (es) | Administracion de agente activo en polvo seco agente activo y un inhibidor del crecimiento higroscopico | |
| ES2190692A1 (es) | Formulacion farmaceutica de amoxicilina y clavulanato de potasio. | |
| CO5271759A1 (es) | Formulacion en solucion que contiene una mezcla de disolventes | |
| ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
| AR018109A1 (es) | FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA | |
| BR0109779A (pt) | Soluções moleculares hidrofìlicas dispersas de carvedilol | |
| BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
| PA8509001A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
| DE60019902D1 (de) | Echinocandin pharmazeutische zusammensetzungen | |
| BRPI0409715A (pt) | pelìculas comestìveis de dissolução rápida contendo um edulcorante | |
| AR038535A1 (es) | Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos | |
| EA200501001A1 (ru) | Фармацевтический состав с нерастворимым активным агентом | |
| AR013506A1 (es) | Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida | |
| BR0215184A (pt) | composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada | |
| UY25544A1 (es) | Forma de dosificación de nefazodona | |
| JP2006528990A5 (es) | ||
| PE20050464A1 (es) | Formulacion farmaceutica de la sal sodica del telmisartan | |
| AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
| AU2002231889A1 (en) | Halogenated composition, method for preparing same and uses thereof | |
| BR0109672A (pt) | Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente | |
| BR0012444A (pt) | Composições de pó seco | |
| AR002993A1 (es) | Una formulación farmaceutica pediatrica en la forma de un polvo seco o en forma de granulado la cual esta adaptada para su reconstirución con agua u otro medio acoso, de amoxicilina y acido clavulanico. | |
| PE20030323A1 (es) | Composicion farmaceutica | |
| MXPA05005046A (es) | Formulaciones parasiticidas topicas y metodos de tratamiento. | |
| BR0309057A (pt) | Formulações lìquidas com baixa dosagem em entecavir e uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |